Literature DB >> 7813326

Pulmonary embolism: epidemiology.

C Giuntini1, G Di Ricco, C Marini, E Melillo, A Palla.   

Abstract

Present evidence suggests that venous thromboembolism is the third most common acute cardiovascular disease after cardiac ischemic syndromes and stroke. The frequency of the diagnosis of pulmonary embolism (PE) at a given hospital greatly increases if a referral unit for PE is set up in the hospital. Pulmonary embolism is characterized by a continuous spectrum of severity, from 2 to 3 to 15 to 16 embolized pulmonary segments (over a total of 19). Morbidity from PE increases with age and male sex (males/females ratio: 1.24). In only a minority (10%) of patients with PE and/or deep-vein thrombosis (DVT), primary deficiencies of coagulation-inhibiting proteins have been shown. Primary abnormalities of the fibrinolytic system seem even more rare. On the basis of the clinical conditions preceding the embolic episode, patients may be divided into different groups: apparently primary or idiopathic PE (40%), surgery or trauma (43%), heart disease (12%), neoplastic disease (4%), and systemic disease (1%). Patients with apparently primary or idiopathic PE often develop subsequent clinically overt cancer (9.1%), whereas surgery or trauma patients rarely do (1.4%). Furthermore, the former exhibit a significantly shorter survival than the latter mostly for causes of death that reflect increased predisposition to thrombogenesis. Thus, as for DVT, it is convenient to consider a primary or idiopathic form also for PE.

Entities:  

Mesh:

Year:  1995        PMID: 7813326     DOI: 10.1378/chest.107.1_supplement.3s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  27 in total

1.  Should we look further for cancer in a patient with venous thromboembolism?

Authors:  D E Arterburn; W S Richardson
Journal:  West J Med       Date:  2000-05

Review 2.  When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg?

Authors:  K M Flegel
Journal:  CMAJ       Date:  1999-04-20       Impact factor: 8.262

Review 3.  Genetics and pulmonary medicine. 4. Pulmonary embolism.

Authors:  M Laffan
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

4.  Unusual Pulmonary Arterial Filling Defect caused by Systemic to Pulmonary Shunt in the Setting of Chronic Lung Disease Demonstrated by Dynamic 4D CTA.

Authors:  Kianoush Ansari-Gilani; Robert C Gilkeson; Edward M Hsiao; Prabhakar Rajiah
Journal:  J Radiol Case Rep       Date:  2015-11-30

5.  Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis.

Authors:  E Attanasio; P Russo; G Carunchio; L Caprino
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

6.  Chest multidetector computed tomography (MDCT) in patients with suspected acute pulmonary embolism: diagnostic yield and proportion of other clinically relevant findings.

Authors:  L Cereser; D Bagatto; R Girometti; G Como; C Zuiani; M Bazzocchi
Journal:  Radiol Med       Date:  2010-12-03       Impact factor: 3.469

Review 7.  The role of computed tomography in the diagnosis of acute and chronic pulmonary embolism.

Authors:  Halil Doğan; Albert de Roos; Jacob Geleijins; Menno V Huisman; Lucia J M Kroft
Journal:  Diagn Interv Radiol       Date:  2015 Jul-Aug       Impact factor: 2.630

8.  Suboptimal CT pulmonary angiography in the emergency department: a retrospective analysis of outcomes in a large academic medical center.

Authors:  David D B Bates; Jaroslaw N Tkacz; Christina A LeBedis; Nagaraj Holalkere
Journal:  Emerg Radiol       Date:  2016-07-27

9.  Management of pulmonary embolism: state of the art treatment and emerging research.

Authors:  Omar Esponda; Alfonso Tafur
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-04

10.  The effects of obesity on venous thromboembolism: A review.

Authors:  Genyan Yang; Christine De Staercke; W Craig Hooper
Journal:  Open J Prev Med       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.